Personalised treatment for Type 2 diabetes could be available soon as researchers have found that yohimbin a drug that was de-registered for several years effectively blocks damaging effects of a gene variant that impairs insulin production. The drug showed promise in both animal experiments as well as in trials with donated human insulin-producing cells. 'Yohimbin neutralised the effects of the risk gene. The carriers of the risk gene gained the same capacity to secrete insulin as those without the risk variant' said principal study author Yunzhao Tang from the Lund University in Sweden. 'The concept of treatment personalised to the